Arcus Biosciences closes public offering of 15.76M shares, net proceeds ~$269.7M

Arcus Biosciences, Inc.

Sold 15,755,000 shares at $18.25 per share including full exercise of underwriters' option.
Net proceeds of approximately $269.7 million after discounts and estimated expenses.
Underwriters led by Leerink Partners LLC and Goldman Sachs & Co. LLC.
Offering closed on November 3, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.